Head-to-head · Value Score
Trimi Health vs Claya
Two GLP-1 deals, scored on the same six factors. Trimi Health lands a Value Score of 89, Claya a 75. Here's who gives you the honest lower price — and where each one bites back.
Trimi Health
#3 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameClaya
#127 · Grade C+ · Fair Price
Est. first month
From $179/mo (starting dose, compounded)
Save ~87% vs brand-nameThe verdict
Trimi Health takes it on Value Score, 89 to 75 — an est. $99/mo first month, with no teaser step-up baked in. Claya isn't out of it: Shoppers who want compounded GLP-1 in injectable and oral-tablet forms with named clinicians.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Trimi Health | Claya |
|---|---|---|
| Value Score | 89 (A) | 75 (C+) |
| Est. first month | $99/mo | From $179/mo (starting dose, compounded) |
| Save vs brand-name | ~93% | ~87% |
| Semaglutide | $99/mo | From $179/mo (starting dose, compounded) |
| Tirzepatide | $125/mo | From $279/mo (starting dose, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Trimi Health
The ultra-budget pick: two-digit semaglutide and a $125 tirzepatide — one of the lowest flat tirz stickers on the whole board — shipped to all 50 states.
Why it's a deal
- Ultra-budget on both molecules — $99 semaglutide and a class-low $125 tirzepatide, flat with no teaser step-up
- Tirzepatide at $125/mo undercuts most of the flat-fee field on the priciest molecule
- Nationwide 50-state reach, so the low price isn't gated to a handful of states
The fine print
- Not LegitScript-certified — do your own pharmacy diligence before you buy on price alone
- Compounded injectable only — no FDA-approved brand-name or oral/sublingual route
- Newer brand with a thin public track record
Claya
Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.
Why it's a deal
- Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
- Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
- Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
- Weight-loss money-back guarantee published on the homepage
- Free expedited shipping included in the monthly price
The fine print
- States-served list not disclosed — you must check at checkout
- LegitScript certification status not displayed
- Corporate legal entity not disclosed on the site or privacy policy
- Oral compounded tablets have weaker efficacy data than injectable semaglutide
- Intro pricing is higher at refill ($299), erasing the first-month advantage
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Trimi Health is ranked on the Trimi Health alternatives board, and the same list for the other side is on alternatives to Claya.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.